Hybrid Lipid Bilayer-Coated Nanoparticles for Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nanoparticle-based drug delivery systems face challenges with stability, biocompatibility, and targeted delivery, particularly in cancer therapy, where they experience uncontrolled drug release, poor solubility, and multi-drug resistance, limiting their efficacy and safety.
Innovation Solution
Development of nanoparticle composites with a hybrid lipid bilayer membrane that includes stabilizing and aggregation inhibitor molecules, allowing for covalent attachment to the nanoparticle core, enhancing stability and biodistribution, and incorporating imaging and targeting agents for precise delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional nanoparticle-based drug delivery systems are used, then drug delivery capability is provided, but stability and biocompatibility are poor leading to uncontrolled drug release and toxicity
Solution Approach 1:
The patent applies composite materials by combining nanoparticle cores with hybrid lipid bilayer membranes to create a multi-component system. The lipid bilayer membrane consists of multiple layers including a hydrophobic chain layer and a polar head group layer, forming a composite structure that provides both stability and biocompatibility. This composite approach resolves the contradiction by integrating materials with complementary properties - the nanoparticle provides drug loading capacity while the lipid membrane provides stability and reduced toxicity.
Solution Approach 2:
The patent employs flexible shells and thin films by using a lipid bilayer membrane that closely mimics natural cell membranes. This thin film structure provides biocompatibility and protects the nanoparticle core, preventing uncontrolled drug release and reducing toxicity to normal cells. The flexible nature of the lipid membrane allows it to adapt to physiological environments while maintaining structural integrity throughout circulation.
2Reliability
If nanoparticle systems are used for drug delivery, then targeted delivery potential is provided, but localization and solubility are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the surface properties of nanoparticles through coating with lipid bilayer membranes. The membrane composition, including hydrophobic chain length and polar head group types, is optimized to achieve both improved solubility in physiological fluids and enhanced localization in target tissues. By adjusting these parameters, the system achieves better biodistribution and reduced aggregation while maintaining targeted delivery capability.
3Reliability
If chemotherapy is used for cancer treatment, then cancer eradication effectiveness is provided, but non-specific distribution to normal and cancer cells causes systematic toxicity
Solution Approach 1:
The patent applies local quality by functionalizing the lipid bilayer membrane with targeting ligands that provide site-specific recognition of cancer cells. Different regions of the nanoparticle system have different functions - the core provides drug loading, the lipid membrane provides stability and biocompatibility, and surface-bound targeting ligands provide selective cancer cell recognition. This spatial differentiation of functions enables selective drug delivery to cancer cells while minimizing exposure and toxicity to normal cells.
4Device complexity
If nanotechnological advances are used for drug delivery, then delivery mechanism improvement is provided, but in vivo stability and biocompatibility challenges remain
Solution Approach 1:
The patent applies the intermediary principle by using a lipid bilayer membrane as a mediator between the nanoparticle core and the physiological environment. This intermediate layer protects the nanoparticle core from degradation in vivo while maintaining controlled drug release capability. The lipid membrane acts as a buffer interface that enhances biocompatibility and stability without compromising the sophisticated delivery mechanism, allowing the system to navigate physiological barriers and achieve targeted delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticle composites demonstrate improved stability, prolonged circulation times, and enhanced biodistribution, enabling effective targeted delivery of therapeutic agents while minimizing toxicity to normal cells and allowing for real-time imaging and monitoring.
Implementation Method 1
stabilizing agent molecules can comprise an aliphatic chain and a heteroatom terminus covalently bound to a surface of the nanoparticle core
Implementation Method 2
a hybrid lipid bilayer, which can comprise one or more stabilizing agent molecules, one or more lipids, one or more aggregation inhibitor molecules
Implementation Method 3
aggregation inhibitor molecules can comprise a hydrophobic chain and a polar terminus
Data Source
AI summary
Disclosed herein are embodiments of nanoparticle composites that comprise covalently coupled stabilizing agent molecules that improve stability of the nanoparticle composites and allow for tight packing of lipids and/or membranes. The nanoparticle composites can further comprise inhibition inhibitors and/or lipid components that interact to form a hybrid lipid bilayer membrane around the nanoparticle core. The nanoparticle composites can be coupled to drugs, targeting moieties, and imaging moieties. The nanoparticle composites can be used for in vivo drug deliver, disease diagnosis/treatment, and imaging.